SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 203 filers reported holding SAGE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $315,162 | -55.6% | 15,314 | +1.4% | 0.00% | -50.0% |
| Q2 2023 | $709,814 | +9.0% | 15,096 | -2.7% | 0.01% | 0.0% |
| Q1 2023 | $650,967 | +13.1% | 15,514 | +2.8% | 0.01% | 0.0% |
| Q4 2022 | $575,533 | +1.7% | 15,090 | +4.5% | 0.01% | 0.0% |
| Q3 2022 | $566,000 | +22.0% | 14,446 | +0.5% | 0.01% | +20.0% |
| Q2 2022 | $464,000 | -2.1% | 14,368 | +0.3% | 0.01% | +25.0% |
| Q1 2022 | $474,000 | -21.8% | 14,331 | +0.6% | 0.00% | -20.0% |
| Q4 2021 | $606,000 | -4.6% | 14,246 | -0.6% | 0.01% | 0.0% |
| Q3 2021 | $635,000 | -21.7% | 14,337 | +0.4% | 0.01% | -28.6% |
| Q2 2021 | $811,000 | -28.5% | 14,283 | -5.7% | 0.01% | -30.0% |
| Q1 2021 | $1,134,000 | -13.0% | 15,150 | +0.5% | 0.01% | -16.7% |
| Q4 2020 | $1,304,000 | +36.1% | 15,075 | -3.8% | 0.01% | +20.0% |
| Q3 2020 | $958,000 | +96.7% | 15,666 | +33.7% | 0.01% | +42.9% |
| Q2 2020 | $487,000 | +39.5% | 11,717 | -3.7% | 0.01% | +16.7% |
| Q1 2020 | $349,000 | – | 12,165 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
| Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
| Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
| BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
| TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
| Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
| RA Capital Management | 350,933 | $49,569,000 | 2.65% |
| Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
| OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |